Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:53:25.025Z.
Calculation as of: 2026-10-06T19:53:25.025Z.
Quote observation: 2026-10-06T19:30:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2871aed35905ca893ff96a4b2ab646902ae69530b401aedab5470ff00d0a486
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$14.17M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.39M
EV/FCF Ratio
12.43x
TTM Avg
13.15x
3Y Avg
13.15x
5Y Avg
13.15x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Optimi Health Corp. (OPTH) | $13.36M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.31M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.14M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.93M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.88M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.17M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.39M | 12.43x | 13.15x | 13.15x | 13.15x |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.63M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
